To view this email as a web page, click
here.
|
Advertisement |
_1796787.jpg) |
|
|
|
|
Saturday, January 16, 2021
|
|
|
Due to COVID-19 restrictions, the Society for Integrative Oncology held its 2020 international conference in a virtual format. It focused on key issues of health disparities in integrative cancer care, innovative integrative oncology service delivery models, and globalization of integrative oncology research and practice.
Electronic health record–based artificial intelligence may help uncover new risk factors in the development of early-onset colorectal cancer, according to study findings presented by Parker et al at the AACR Virtual Special Conference: Artificial Intelligence, Diagnosis, and Imaging. Disorders that cause chronic immunosuppression or inflammation—such as human immunodeficiency virus, obesity, asthma, sinusitis, and dermatitis—were identified as new risk factors for young-onset colorectal cancer by machine-learning models.
The U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to cavrotolimod (AST-008). The designations include cavrotolimod in combination with anti–PD-1 therapy for the treatment of patients with locally advanced or metastatic Merkel cell carcinoma refractory to prior anti–PD-1 blockade, and cavrotolimod in combination with anti–PD-1/anti–PD-L1 therapy for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma refractory to prior anti–PD1/PD-L1 blockade.
|
|
The 2021 Gastrointestinal Cancers Symposium, held in a virtual format this year, is taking place from January 15 to 17. We're discussing findings from the meeting with three study authors.
|
|
NEWSREELS FROM THE 2021 Gastrointestinal Cancers Symposium |
|
|
|
|
TRENDING IN PROSTATE CANCER |
|
|
In a study reported in JAMA Oncology, Jensen et al found that clonal hematopoiesis of indeterminate potential involving DNA repair genes can interfere with prostate cancer plasma cell-free DNA testing used to determine eligibility for PARP inhibitor treatment and produce false-positive results in a sizable proportion of patients.
In a study examining the effect of a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style diet fared better over the course of their disease than men whose diet did not follow these principles. These findings were published by Gregg et al in the journal Cancer.
In a National Cancer Database analysis reported in JAMA Network Open, Patel et al found that treatment at facilities with high vs low radiation case volumes was associated with improved overall survival in men with node-positive prostate cancer receiving curative-intent external-beam radiation therapy and androgen-deprivation therapy.
A research team has published findings from a study that brought together data from genomic prostate cancer studies. Including more than 200,000 men of European, African, Asian, and Hispanic ancestry from around the world, the study is reportedly the largest, most diverse genetic analysis ever conducted for prostate cancer. The findings were published by Conti et al in Nature Genetics.
|
|
|
|
|
|
|
|
|
|
Visit The ASCO Post Online at ASCOPost.com
Or
Visit and Follow Us
|
|
The ASCO Post™ is published by Harborside Press, LLC under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in The ASCO Post™ do not necessarily reflect those of Harborside Press, LLC, HSP News Service, LLC, or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Harborside Press, HSP News Service, LLC, and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions. |
|
|
|
|
INSERT_DYNAMIC_CONTENT_BLOCK_34492 |
|